KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $25.6 million.

  • Aquestive Therapeutics' Total Current Liabilities rose 6878.3% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 6878.3%. This contributed to the annual value of $18.9 million for FY2024, which is 304.24% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Total Current Liabilities stood at $25.6 million, which was up 6878.3% from $23.2 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Total Current Liabilities high stood at $40.4 million for Q1 2023, and its period low was $13.9 million during Q2 2024.
  • In the last 5 years, Aquestive Therapeutics' Total Current Liabilities had a median value of $23.2 million in 2025 and averaged $25.0 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 7996.72% in 2022, then plummeted by 6405.19% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Total Current Liabilities (Quarter) stood at $22.0 million in 2021, then surged by 79.97% to $39.5 million in 2022, then tumbled by 53.68% to $18.3 million in 2023, then rose by 3.04% to $18.9 million in 2024, then skyrocketed by 35.56% to $25.6 million in 2025.
  • Its last three reported values are $25.6 million in Q3 2025, $23.2 million for Q2 2025, and $18.3 million during Q1 2025.